Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02197975 · ClinicalTrials.gov registry record · Phase 1
Randomized, Crossover Safety and Pharmacokinetics Study of PT010
A Phase 1 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02197975 is a Phase 1 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT02197975, a Phase 1 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Safety and Pharmacokinetics of Two Doses of PT010 in Healthy Adult Subjects of Japanese Descent Following a Single Dose and After Chronic Dosing for 7 Days.
Interventions
- DRUG Placebo MDI
- DRUG PT010 Dose 1
- DRUG PT010 Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02197975
The ClinicalTrials.gov registry entry for NCT02197975 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo MDI is the first listed.
NCT02197975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02197975 about?
NCT02197975 is a clinical study titled "Randomized, Crossover Safety and Pharmacokinetics Study of PT010". Safety and Pharmacokinetics of Two Doses of PT010 in Healthy Adult Subjects of Japanese Descent Following a Single Dose and After Chronic Dosing for 7 Days.
What is the current status of trial NCT02197975?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-08. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02197975?
The interventions under investigation include: Placebo MDI (DRUG), PT010 Dose 1 (DRUG), PT010 Dose 2 (DRUG).
Who is sponsoring clinical trial NCT02197975?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.